<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655186</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-1202</org_study_id>
    <nct_id>NCT01655186</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled Phase 2 safety study will&#xD;
      assess the effect of bardoxolone methyl relative to placebo on body weight and fat mass in&#xD;
      approximately 60 patients with stage 4 Chronic Kidney Disease (CKD) and Type 2 Diabetes&#xD;
      Mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IDMC recommendation for safety concerns&#xD;
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in body weight as measured by Dual Energy X-ray Absorptiometry (DXA)</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>DXA to be done 14 days prior to or after the weeks 12 and 24 visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in fat mass as measured by Dual Energy X-ray Absorptiometry (DXA)</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>DXA to be done 14 days prior to or after the weeks 12 and 24 visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat mass measured by Magnetic Resonance Imaging of the abdomen</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>MRI to be done 14 days prior to or after the week 24 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic fat mass as measured by Magnetic Resonance Imaging of the liver</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>MRI to be done 14 days prior to or after the week 24 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular structure and function as measured by gated Magnetic Resonance Imaging of the heart</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>MRI to be done 14 days prior to or after the weeks 12 and 24 visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gait speed</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, intensity and relationship of study drug to adverse events and serious adverse events, as well as clinical, and laboratory test result abnormalities</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bardoxolone Methyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone Methyl</intervention_name>
    <arm_group_label>Bardoxolone Methyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Screening eGFR ≥ 15.0 and &lt; 30.0 mL/min/1.73 m2; screening eGFR will be the average of&#xD;
             the eGFR values collected during screening;&#xD;
&#xD;
          2. A history of type 2 diabetes mellitus; diagnosis must have been made at ≥ 30 years of&#xD;
             age;&#xD;
&#xD;
          3. Male or female patients at least 30 years of age;&#xD;
&#xD;
          4. Treatment with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin&#xD;
             II receptor blocker (ARB) for at least 6 weeks prior to Screening Visit A and during&#xD;
             screening. The dosage of ACE inhibitor and/or ARB must be at KDOQI goal dose (Appendix&#xD;
             13.4) and stable for 2 weeks prior to Screening Visit A and during screening (i.e., no&#xD;
             change in dosage or medication);&#xD;
&#xD;
          5. Mean systolic blood pressure (SBP) must be ≤ 160 mmHg and ≥ 105 mmHg and mean&#xD;
             diastolic blood pressure (DBP) must be &lt; 90 mmHg during screening visits A and B;&#xD;
&#xD;
          6. Willing to practice methods of birth control (both males who have partners of&#xD;
             childbearing potential and females of childbearing potential) during screening, while&#xD;
             taking study drug and for at least 30 days after the last dose of study drug is&#xD;
             ingested;&#xD;
&#xD;
          7. Serum magnesium level must be greater than or equal to 1.3 mEq/L at Screening Visit B&#xD;
             or during a subsequent unscheduled visit during screening (serum magnesium level may&#xD;
             be re-evaluated once during an unscheduled visit);&#xD;
&#xD;
          8. Willing and able to give written informed consent for study participation and&#xD;
             cooperate with all aspects of the protocol including tolerating being in a closed MRI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Type 1 diabetes mellitus. If a history of diabetic ketoacidosis exists, a fasting C-peptide&#xD;
        level must confirm type 2 diabetes; 2. Known non-diabetic renal disease (e.g., polycystic&#xD;
        kidney disease, focal segmental glomerulosclerosis) [nephrosclerosis superimposed on&#xD;
        diabetic kidney disease is acceptable]; Ongoing clinical investigation with evidence (e.g.,&#xD;
        unexplained hematuria or red blood cell or white blood cell casts) suggesting non-diabetic&#xD;
        renal disease other than nephrosclerosis; 4. History of a renal transplant or a planned&#xD;
        transplant from a living donor during the study; 5. Urine albumin/creatinine ratio (UACR)&#xD;
        at Screening Visit B greater than 3500 mg/g; 6. Hemoglobin A1c level &gt; 11.0% during&#xD;
        screening; 7. Acute dialysis or acute kidney injury within 12 weeks prior to screening or&#xD;
        during screening; 8. Clinical signs and/or symptoms of uremia and expected need for renal&#xD;
        replacement therapy within 12 weeks following randomization, as assessed by the&#xD;
        investigator; 9. Recently active cardiovascular disease defined as:&#xD;
&#xD;
          -  Unstable angina pectoris within 12 weeks before study randomization;&#xD;
&#xD;
          -  Myocardial infarction, coronary artery bypass graft surgery, or percutaneous&#xD;
             transluminal coronary angioplasty/stent within 12 weeks before study randomization;&#xD;
&#xD;
          -  Cerebrovascular accident, including transient ischemic attack, within 12 weeks before&#xD;
             study randomization;&#xD;
&#xD;
          -  Current diagnosis of Class III or IV NYHA congestive heart failure (Appendix 13.3);&#xD;
             10. Clinical diagnosis of severe obstructive valvular heart disease or severe&#xD;
             obstructive hypertrophic cardiomyopathy; 11. Atrioventricular block, 20 or 30; 12.&#xD;
             Implanted medical device that would prevent obtaining a MRI; 13. Administration of a&#xD;
             contrast agent that may induce nephropathy within 30 days prior to study randomization&#xD;
             or planned during the study; 14. Systemic immunosuppression for more than 2 weeks,&#xD;
             cumulatively, within the 12 weeks prior to randomization or anticipated need for&#xD;
             immunosuppression during the study; 15. Total bilirubin, aspartate transaminase (AST),&#xD;
             or alanine transaminase (ALT) level greater than the upper limit of normal (ULN) or&#xD;
             alkaline phosphatase level greater than two times the ULN on ANY screening laboratory&#xD;
             test result; 16. Female patients who are pregnant, intend to become pregnant during&#xD;
             the study, or are nursing; 17. BMI &lt; 18.5 kg/m2; 18. Weight ≥ 300 pounds; 19. Height &gt;&#xD;
             6'3&quot;; 20. Partial or total amputation of a lower extremity prior to randomization; 21.&#xD;
             Known hypersensitivity to any component of the study drug; 22. Current history of drug&#xD;
             or alcohol abuse, as assessed by the investigator; 23. Clinically significant&#xD;
             infection requiring intravenous administration of antibiotics or hospitalization&#xD;
             within 6 weeks prior to Screening Visit A or during screening; 24. Hepatitis B surface&#xD;
             antigen positive; Diagnosis or treatment of a malignancy in the past 5 years,&#xD;
             excluding non-melanoma skin cancer and carcinoma in situ of the cervix or a condition&#xD;
             highly likely to transform into a malignancy during the course of the study; 26.&#xD;
             History of bariatric surgery or planned bariatric surgery during the course of the&#xD;
             study; 27. A clinical condition that, in the judgment of the investigator, could&#xD;
             potentially pose a health risk to the patient while involved in the study; 28.&#xD;
             Participation in a clinical study involving any intervention within 30 days prior to&#xD;
             randomization, concurrent participation in such a study, or participation in a prior&#xD;
             clinical study involving bardoxolone methyl in any form; 29. Unable to communicate or&#xD;
             cooperate with the investigator due to language problems, poor mental development, or&#xD;
             impaired cerebral function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>July 30, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2012</study_first_posted>
  <last_update_submitted>October 19, 2012</last_update_submitted>
  <last_update_submitted_qc>October 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

